14,274 Shares in NeoGenomics, Inc. (NEO) Acquired by Empirical Finance LLC
Empirical Finance LLC bought a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,274 shares of the medical research company’s stock, valued at approximately $159,000.
Several other large investors also recently bought and sold shares of NEO. Vanguard Group Inc. raised its position in shares of NeoGenomics by 1.7% in the second quarter. Vanguard Group Inc. now owns 2,724,603 shares of the medical research company’s stock worth $24,413,000 after buying an additional 44,820 shares in the last quarter. First Light Asset Management LLC raised its position in shares of NeoGenomics by 1.0% in the second quarter. First Light Asset Management LLC now owns 2,679,271 shares of the medical research company’s stock worth $24,006,000 after buying an additional 25,617 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of NeoGenomics in the second quarter worth $20,651,000. Russell Investments Group Ltd. raised its position in shares of NeoGenomics by 66.1% in the second quarter. Russell Investments Group Ltd. now owns 1,996,710 shares of the medical research company’s stock worth $17,891,000 after buying an additional 794,281 shares in the last quarter. Finally, Granite Investment Partners LLC increased its stake in NeoGenomics by 52.4% in the second quarter. Granite Investment Partners LLC now owns 1,976,020 shares of the medical research company’s stock valued at $17,706,000 after acquiring an additional 679,778 shares during the last quarter. Hedge funds and other institutional investors own 80.19% of the company’s stock.
A number of research firms recently commented on NEO. BTIG Research reissued a “hold” rating on shares of NeoGenomics in a research note on Sunday, October 29th. Janney Montgomery Scott reissued a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. BidaskClub raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 23rd. Finally, ValuEngine raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $10.33.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/14274-shares-in-neogenomics-inc-neo-acquired-by-empirical-finance-llc/1682562.html.
Shares of NeoGenomics, Inc. (NASDAQ NEO) traded up $0.27 during trading hours on Monday, hitting $8.94. The stock had a trading volume of 56,050 shares, compared to its average volume of 549,262. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.37 and a quick ratio of 2.21. The stock has a market capitalization of $688.29, a P/E ratio of 173.40, a PEG ratio of 6.84 and a beta of 0.84.
NeoGenomics (NASDAQ:NEO) last announced its earnings results on Wednesday, October 25th. The medical research company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $63.05 million for the quarter, compared to analysts’ expectations of $63.11 million. NeoGenomics had a positive return on equity of 3.98% and a negative net margin of 4.78%. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.04 earnings per share. research analysts predict that NeoGenomics, Inc. will post 0.06 earnings per share for the current fiscal year.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.